.
ࡱ > \ p e_fomicheva B a = = h,\: 8 X@ " 1 " A r i a l C y r 1 " A r i a l C y r 1 " A r i a l C y r 1 " A r i a l C y r 1 " A r i a l C y r 1 " A r i a l C y r 1 " A r i a l C y r 1 ̅A r i a l 1 " A r i a l C y r ""#,##0;\-""#,##0 ""#,##0;[Red]\-""#,##0 ""#,##0.00;\-""#,##0.00 # ""#,##0.00;[Red]\-""#,##0.00 5 * 0 _-""* #,##0_-;\-""* #,##0_-;_-""* "-"_-;_-@_- , ) ' _-* #,##0_-;\-* #,##0_-;_-* "-"_-;_-@_- = , 8 _-""* #,##0.00_-;\-""* #,##0.00_-;_-""* "-"??_-;_-@_- 4 + / _-* #,##0.00_-;\-* #,##0.00_-;_-* "-"??_-;_-@_- , * + ) @ @ $@ @ $@ @ 8@ @ `
u PRICE , !
;
L " . b & L С|GQ n L С|GQ PNG
IHDR gAMA PLTE ٟ pHYs ." ."ݒ yIDATxݻ8 `grSh -DHIAIc 7`LE9ASLQL|}8egZ+ؿoIDՀG #xK,L-'mf\ @ŰSP8\ Q{V'2dQJ0L
g QO W LP !h3%脠u Ѵk,hՈ@0Lb M5)¢ gvY+a݈j^RP.J>t9KW
jڱj)cnelDQH()}6 .We/>
MD0 J',K^4`BSL-?# ɂv0 l{' q-T X5eGӿ/2_~F\j近[%O 6$(('AyxM_,(KZ~\9Z tÂ~&jaGq٢ }%5|.+G&RMoO8`LH/ 3ACP@b i5.hA"@ W
Z^W
x ^)7$^' C\ReFql{oZฐGk7.iAyWφ_VX_+
k|MBAy/:$N>?|ﱼZ7 z QcR}X @v@PQ8KuV+!&j;dp*y B$1O@E`Nd`P@%0_P 3_xe
K H&"(W\E *ȭ ^N&J@"|-?dIDٌ@A崢fA0fIP]kK%Y /V/G .r+ߨqr 9!T,Db `
<.5{&6]K
z@
dC( |TNkGV&wDI(o'M:8.-L,5ѐ39@
A/j%"A~ ,wHrU ҂ f(oB-N?qcky IC` YsϾq ̈ ?pΖ-|
yui-9Zd G9F`GFȦ |eP8e`X""
Я EOAu>S " \ G@o*LP#jl idoS+ T?
ʻ e]( *pzX|[{E24ܢ SCǰR K 8-`vHWZ$y´=*>qHdZőePY'
v[Sx^Y|K֬ \3.( A^,A_ v_Ay@BAXW"NDU>㙫Z(Ԃ?& !3|]W6L
Ae J fC@XwF-`A^0. O,1J@.VJ\[yPXh[Jm\c aAeh[X+ဠU1(Ł)0 v { DuHJ@Tꎀ tIڊA?A:\PSW
K2{ F3+x]qIPu3R )Ow8,UDI4t %@vu=LPN $h1A7 \ R,Ȩni&
-
ĝod2C20w}S}.h&$GC Ӵ0R,hx| õg`ʵV@l{k V,Ct%UUwT`?owAOlIP$
oWbCHf dZxoEE*8F uH J? (Pm \y^Jybzf] ƾJ@t.lY4 ߒ #sH,@ )P'*0u20\`vITql\ 5v >75j8~lmo"2If$h@l ]JA(03G=bdȮ K й,t+{zP(?㛷H zR *Y&00-
:x$F ~`Bq` 3+ F'Dsɢ8կ*Wɢ@Nm@u и, > cX@k2՛+pw sXXDHB$SZ4>rE%Ł|l ז 9,$`AQl}KL fM@Ф
@ ~cѓ xdž'7UVA;o%k`۰&z M4= :Ob80 2F(r?W@Ѭȉ9?9E6x9ča
z7G B9Z vy` ,q@'5F-hR tv 72V ~^ Zb N I+hFx .
Tk8i.D+p~9<ӷG #xA;K9 B01. !2 0 =0D5@>= 45BA:89 B01. !2 0 =0D@0=8; 0<?. 2 5 <3 2 2 5 ;<54 =38=- E5;L ! B01. !5 0 Biologische Heilmittel Heel GmbH Torrent Labor. =48?0; B01. !1 0 AD0@:C@ B01. 1 0 :C@ B01. 5 0 <3 !2 0 F.Hoffmann-La Roche Ltd =5AB578= B01. 3 0 0 ; A25G8 !1 0 =65;8: B01. !2 8 =8A ?;>4K 5 0 34 ICN Pharmaceuticals Switzerland Ltd (Solco Basle AG) =B0:A>= :0?A. 5 0 @@@;8F09 B01. !2
$;09=0 =B8- ?>;8F09 B01. !4 2 =B8- $;C 84A ?>@. 4/ ?@83. @- @0 4/ ?@85@. !5 =B8- D;C B01. !1 2 % =B8- - D;. 2 5 1;53G5=85 ?>E<5;LO) Rusan Pharma =B83@8??8= H8?. B01. !1 0 =B83@8??8=- :0?A. !2 0 =B828@0; =B83@8??8=- 0:A8<C:A8:0?A :0?A. !2 0 =B8>:A8:0?A A A5;5=>:A8:0?A A F8=:>EE<5;8= " =B8?" B01. 0 , 5 3 !6 =B8A:;5@8= :0?A. !3 0 Diet Pharma Pharmaton S.A. =B8AB0:A :0?A. 1 8 0 ;5AB5@8= B01. !3 0 ( ) Calze GT =B8H;0: B01. !1 0 =B>F80= D>@B5 B01. 0 , 4 <8@# ?0C@8= @- @ 4/ 8=. 1 0 <3 0<?. 2 AA89A:89 :0@48>;. / 0AB5@;5: ?870@B@>= <07L 2 0 3 Esparma GmbH ?8;0: <07L 3 % BC10 5 0 3 ?8;0: B01. 1 0 ? 1 0 0 78BC2538= 0<?. 2 2538= 0<?. 4 0 0 <3 1 0 2538= 0<?. 5 2538= 35;L 2 0 % 2 0 3 :B>2538= :@52538= 2538= @- @ 4/ 8=. 4 0 <3/ <; 0<?. 5 2538= @- @ 4/ 8=D. A 3;N:>7>9 1 0 % D;. 2 5 0 2538= @- @ 4/ 8=D. A E;>@84>< =0B@8O 1 0 % D;. 2 5 0 2538= @- @ 4/ 8=D. A E;>@84>< =0B@8O 2 0 % D;. 2 5 0 <; !1 Novo Nordisk7 :B@0?84 5=D8;; @- @ 4/ 8=. 1 0 0 / <; :0@B@8468 3 <; !5 ' :B@0?84 @- @ 4/ 8=. 1 0 0 \ <; D;. 1 0 !5 0 Alkaloid& ;5:A ;NA ?0AB8;:8 4/ @0AA0AK20=8O !2 0 Glenmark Pharma% ;5:A ;NA ?0AB8;:8 4/ @0AA0AK20=8O !4 Heinrich Mack nachf." SUN Pharmaceutikal Industries Ltd. Lilly France S.A.S.
=0B $0@<0 B a y e r A G ( 157@5F5?B. ) ;:0- 75;LF5@ H8?. B01. !1 0 ;:5@0= B01. 2 2 30; B01. H8?CG85 !1 2 >A:>2A:0O D0@48; 3;. :0?;8 0 , 0 5 % D;. 6 48; A?@59 =070;L=K9 1 0 1 0 ?C@8=>; B01. 0 , 1 3 !5 0 ;;>?C@8=>;- -38A B01. 1 0 0 ?C@8=>;- -38A B01. 3 0 0 ?C@8=>;0 B01. 1 0 0 E>; B01. ?/ > !1 0 0;LE8<D0@<$ $0@<A:E8<D0@A8=B57 ;>M ;8=8M A>: D;. 5 0 M B01. ?/ > !2 0 ;>M M:AB@0:B 684:. 0<?. 1 ;0< B01. 1 AB0= :>=F5=B@0B 4/ 8=D. 0<?. 0 , 1 <3/ 0 , 2 @=8 ?0G:0 7 5 3 ;B59 A8@>? D;. 1 5 0 <; 0;8GD0@? D;. 1 2 5 3 ;B8075< :0?A. 1 8 0 @8B;L=8: B01. !6 0 ;D08B -DD5:B B01. !3 0 ;D;CB>? 0<?. 1 0 <3/ <; !1 0
Biotechnos SA ;L10@5; B01. 1 A:20 8:@>35= $# Searle Pliva Schering-plough Schering-Plough Labo N.V. ;L:0- @8< H8?. B01. !1 0 Polpharma ;LD0 3 - "520 :0?A. 0 , 2 5 =0 ;8>D. 4/ ?@83. @- @0 4/ 8=B@0=07. 2254. 5 0 BKA. D;. !1 ( 2 :><?;5:B5 A @- ;5<) $0@= Alfa Wassermann spa )5;:>2A:89 28B0<. 7- 4 Aventis Pharma <0@8; B01. 4 <3 !3 0
Hoechst AG <15= @- @ 4/ 8=. 1 % 5 <; !1 0 $0@<70I8B0 & 15=5 0<?. 1 5 <3 !5 0 15=5 @- @ 4/ ?@85<0 2=CB@L 7 , 5 <3/ <; D;. 1 0 0 <;/ 15=5 @- @ 4/ ?@85<0 2=CB@L 7 , 5 <3/ <; D;. 4 0 <; 15=5 A8@>? 1 5 <3\ 5 <; 1 0 0 <; 15=5 B01. 3 0 <3 !2 0 15=5- @5B0@4 :0?A. 7 5 <3 !1 0 15=5- @5B0@4 :0?A. 7 5 <3 !2 0 ! 35:A0; :0?A. @5B0@4 7 5 <3 !1 0 Hexal* 35:A0@0;L=K9 7 , 5 <3/ <; D;. 5 0 <;" 35:A0; A8@>? D;. 3 <3/ <; 1 0 0 <; 35:A0; B01. 3 0 =D0@40:H=% !:>?8=A:89 D0@4 ) :A>;- @0? 1 5 <3/ 5 <; D;. 1 0 0 <; Vramed+ :A>;- %5D0@? 1 5 <3/ 5 <; D;. 1 0 0 <;% :A>;- %5D0@< B01. H8?. 3 0 <3 !2 0 % :A>;- %5D0@< B01. H8?. 6 0 <3 !1 0 Hemofarm koncern A.D A0= B01. 3 0 <3 !2 0
Pro.Med.Cs <83@5=8= B01. 1 0 0 D0@< <83@5=8= B01. 5 0 <3 !2 <8:0F8= AC;LD0B D;. 0 , 5 3 @0AD0@<0 = :@5< 1 % 2 0 3 BC10
Eczacibasi 1 2 5 <3 !1 0 0;LE8<D0@</ 0AB5@;5: 1 2 5 <3 !6 6 0 2>A81E8<D0@@1 <8=078=- . !. 4@. 0 , 1 3 !1 0 <8=078=- . !. 4@. 1 0 0 <3 !1 0 <8=078=- . !. 4@. 2 5 <3 !1 0 <8=078=- . !. 4@. 5 0 <3 !1 0 $ :0?@>=>20O :8A;>B0 D;. 5 % 1 0 0 <;7 :0?@>=>2>9 :- BK @- @ 4;O 8=DC788 D;. 5 0 <3/ <;, 1 0 0 <;+ ?;07<0;L 5?0 @- @ 1 0 % 4/ 8=D. D;. 5 0 0 <;' ?;07<0;L 5 % @- @ 4/ 8=D. D;. 5 0 0 <;) AB5@8; N - 35?0 8 % @- @ 4/ 8=D. D; 5 0 0 <;( S I L C A P r o p o l i s E n e r g y ?0AB0 7C1=0O 1 0 0 <;/ S I L C A 45BA:0O :;C1=8G=0O 7C1=0O ?0AB0 7 5 <; BC10/ S I L C A 45BA:0O A :0;LF85< 7C1=0O ?0AB0 5 0 AA<5B. D- :0 Slovakofarma, J.S.C./ V I T A S K I N :@59 1 0 0 <; BC10. V I T A S K I N :@59 5 0 <; BC108 V I T A S K I N :@5< ;53:89 ?8B0B5;L=K9 " B i o B a l a n c e " 5 0 <; 10=:0= V I T A S K I N :@51>30I5==K9 ?8B0B5;L=K9 " B i o B a l a n c e " 5 0 <; 10=:0C V I T A S K I N :@5:@C3 3;07 " B i o B a l a n c e " D;. - 4>70B>@ 3 0 <;( V I T A S K I N :@5A;5 45?8;OF88 7 5 <; BC10. V I T A S K I N ;>G:> >G8I0NI55 >3C@5G=>5 D;. 2 0 0 <;2 V I T A S K I N ;>G:> >G8I0NI55 M:AB@0 5 D;. 2 0 0 =8: M:AB@0 G8I0NI89 D;. 2 0 0 <; $8@=- SCAT Laboratories$ 10:B0; @- @ 4/ 8=. 0<?. 4 0 0 <3 5 4 0 0 =F. 4/ 8=D. 6 <3/ <; D;. 5 AE8<D0@<K 4 5 3 ( 3 0 3)
0;L 4 8 :A B01. ?/ > 4 0 0 <3 !5 Boiron Laboratoires 0B5@80 548:0= - :0@0?0B. !1 5 ( >B C:0G820=8O 2 B@0=A?>@B5) / - B01. !2 0 ( >B C:0G820=8O 2 B@0=A?>@B5) 2>40@B :0?A. 0 , 5 40@B :0?A. 0 , 5 =F. 4/ ?@83. @- @0 4;O 2/ 2 8 2/ 0@B. 2254. 2 0 <3/ <; 0<?. 5 <; !5 Zentiva& 30?C@8= @- @ 4/ 8=L 2 0 <3/ <; 0<?. 5 <; !5 30?C@8= @5B0@4 B01. 4 0 0 4 0 0 6 0 0 1 0 0 ?0B8G5A:89) 1 0 3+ 1 0 3. 45BA:89 ( 0=B83@8??8= 3>?0B8G5A:89) 2 0 3 45BA:89 B01. !4 0 - >@<0 :0?A. 0 , 2 4 !6 0 & $ / ! 40;0B ! @5B0@4 B01. 2 0 ?0B8G5A:0O D0@<0F8O $0@= ;09=D0@:>@ 420=B0= :@5< 0 , 1 % BC10 1 5 3 Schering AG" 420=B0= <07L 68@=0O 0 , 1 % BC10 1 5 3. 420=B0= M<C;LA8O 4/ =0@C6. ?@8<. 0 , 1 % BC10 2 0 3 AWD FreseniusH 448B820 M C;LB828B0 2:CA>?8G5A:8E D@C:B>2) NP Pharma Sp. z o.o. Chinoin 45;LD0=- M784@5:A B01. !2 5 0 Novartis Enterprises Sandoz Private Limited 45;LD0=- -784@5:A B01. !3 0 Biopharm-Romferchim AGIO! 468A5?B ?0AB8;:8 !2 4 <54 8 ;8= 1>;5=A:>5 D0@=8A- 1@> !2 5 >@8A>2A:89 702>4 4>@>2L5 %$ >A:. M=4>:@8==K9 702>4 4@5=0;8=0 3/ E; 0<?. 0 , 1 % 1 ; :0?;8 =070;L=K5 4/ 27@>A;KE D;. 1 0 ; :0?;8 =070;L=K5 4/ 45B59 D;. 1 0 @. 4/ 8=. D;. 1 0 <3 A @- ;5@. 4/ 8=. D;. 5 0 <3 8=A:8=B5@:0?A 5;<54?@5?0@0BK& 528B :0?A. !1 0 / 2- N<8 86D0@D0@< #D8<A:89 28B0@. 4/ ?@83. 2/ 2 8 2/ ?@8= B01. 5 0 <3 !5 0 0:87- $0@<0 70D5= B01. 2 5 : :0?A. 2 5 0 ?8=A:89 D0@:A :0?A. 2 5 0 <3 !6 $0@<8F8= :0?A. 2 5 0 @>2L5 !8=B57 78B CA :0?A. 2 5 0 <3 !6 $0@@>2L5 @0A=>3>@A:;5:A@54AB20 R o c h e ( @5F5?B. ) R o c h e ( 157@5F5?B. ) # :0B8=>; 5 1 0 ; 5 1 0 <3 !9 0 Jadran+ :20- 0@8A A?@59 3 0 A0 ( 2>40 @A:0O) 5>28BG :2045B@< 8;5:0;LF8D5@>;) :0?;8 4/ ?@85<0 2=CB@L 1 5 0 0 0 / <; D;. 1 0 <;. Medana Pharma Terpol Group Joint Stock CompanyA :2045B@84=. 4/ ?@85<0 2=CB@L ( :0?;8) 1 5 0 0 0 / <; D;. 1 0 4=K5 B5E=>;>388 8 = ::C- '5: !>DB:;8:A ;0=F5BK !2 5 ' R o c h e ( 4803=>AB8:0) / B o e h r i n g e r M a n n h e i m 3 ::C- '5: !>DB:;8:A CAB@>9AB2> 4/ ?@>:0;K20=8O ?0;LF0
Goedecke GmbH ::C?@> B01. ?/ > 1 0 B01. ?/ > 2 0 <3 !3 0 ! :=5 :@5B C3@59 4- @0 "09A0 3 0 3 :=5 ;>AL>= 4- @0 "09A0 D;. 1 0 0 <; 09 AstraZeneca :>;0B B01. ?/ > 2 0 <3 !2 8 ) :@845@< " :@5< 4/ =0@. ?@8<. 1 5 3 BC10) :@845@< " :@5< 4/ =0@. ?@8<. 3 0 3 BC10 :@845@< :@5< 1 5 3 BC10 :@845@< :@5< 0 , 0 6 4 % 1 5 3 BC10 :@845@< :@5< 0 , 0 6 4 % 3 0 3 BC10* :@845@< :@5< 4/ =0@. ?@8<. 0 , 0 6 4 % BC10 1 5 3 :@845@< ! <07L 1 5 3 BC10 :@845@< ! @. 4/ ?@83. @- @0 4;O 2/ 2 8 2/ @ @>AB0 2>;>A 4/ BCA:;KE 8 ?>2@564. 2>;>A ?0:5BK 1 5 3 !3 " >;>B>9 H5;:" 0@>4=K5 @>@ @>AB0 2>;>A 4/ C:@5?;. :>@=59 >B 2K?04. 2>;>A ?0:5BK 1 5 3 !3 " >;>B>9 H5;:" R :B820B>@ @>AB0 2>;>A 4/ C:@5?;. B>=:8E 8 A;01KE 2>;>A ?0:5BK 1 5 3 !3 " >;>B>9 H5;:" $0@5:B 3 :B8;875 ;8>D. ?>@. 4/ 8=. D;. 5 0 <?;. A @- ;5; 3;. :0?;8 0 , 0 0 7 % D;. 5 <; 80D0@< :B8D5@@8= :0?;8 3 0 <; Ludwig Merckle :B8D5@@8= :0?A. 3 0 0 <3 !2 0 :B8D5@@8= :0?A. 3 0 0 <3 !5 0 0820=85
@>872>48B5;L !2>1>4=>- $0@@B >3 457>4>@8@CNI0O ?0:. 2 5 3 !1 0 !0=:B- 5B5@1C@3A:0O D. D. * 5 20==0 4/ =>3 A 5 :@53 70682;ONI89 A 3> 45@520 BC10 3 0 3; 5 :@53 70682;ONI89 A >1;5?8E>2K< < BC10 3 0 3D 5 :@53 C2;06=ONI89 A 3@04=>9 :>AB>G:8 BC10 3 0 3) 5 :@5B ?>B0 8 70?0E0 =>3 BC10 3 0 3- 5 ;>AL>= 4/ =>3 >B ?>B0 8 70?0E0 D;. 5 0 3 1 2 0 3* 5 A@54AB2> 4;O =>3B59 A<O3G0NI55 1 0 >B ?>B0 8 70?0E0 =>3 2 3 !1 0 Balkanpharma 5 - =>: B01. ?/ > 5 0 B5:A Ebewe* 5 - DB>@C@0F8; :>=F. 4/ 8=D. D;. 2 5 0 <3 5 @C@0F8;- -1525 :>=F. 4/ 8=D. 5 0 <3/ <; D;. 1 0 >A<5B8G5A:0O D01@8:0S E v i n a l ;>G:> 4/ A=OB8O @<. 8 A68 BC10 1 5 0 <; -28=0;L M E v i n a l 10;L70=48F8>=5@ A M:AB@. ?;0F5=BK 4/ CA8;5=8O @>AB0 2>;>A D;. 2 5 0 <;. E v i n a l :@5< 4/ 25: A M:AB@. ?;0F5=BK 10=:0 1 5 <;- E v i n a l :@53 A M:AB@. ?;0F5=BK BC10 7 5 <;- E v i n a l :@5< 4/ @C: A M:AB@. ?;0F5=BK BC10 7 5 <;? E v i n a l :@5< 4/ B5;0 0=B8F5;;N;8B=K9 A M:AB@. ?;0F5=BK BC10 1 5 0 <;V E v i n a l :@5:@0I5=8O @0ABO65: A M:AB@. ?;0F5=BK BC10 1 5 0 E v i n a l :@51J5<0 3@C48 A M:AB@. ?;0F5=BK BC10 7 5 <;C E v i n a l :@5< 4/ C40;5=8O ?83<5=B=KE ?OB5= A M:AB@. ?;0F5=BK BC10 7 5 <;9 E v i n a l :@5;LB5 A M:AB@. ?;0F5=BK 10=:0 5 0 <;0 E v i n a l :@59 A M:AB@. ?;0F5=BK 10=:0 5 0 <;/ E v i n a l :@5G=>9 A M:AB@. ?;0F5=BK 10=:0 5 0 <;/ E v i n a l :@5<- <0A:0 A M:AB@. ?;0F5=BK 10=:0 5 0 AL>= A M:AB@. ?;0F5=BK 4/ C:@5?;5=8O 2>;>A 1 5 0 =- @0A?K;8B5;LA E v i n a l ?8B0B5;L=0O 2 2>;>A A ?;0F5=B>9 D;. 2 5 0 @>B:0 4/ 2>;>A A M:AB@0:B>< ?;0F5=BK 1 5 0 =- @0A?K;8B5;L. 9 E v i n a l H0;>A D;. 2 5 0 <;8 E v i n a l H0@;>A D;. 2 5 0 <;K E v i n a l H0:@0H. 8 A E89 2>;>A D;. 2 5 0 <;8 E v i n a l H0;>A D;. 2 5 0 <;T E v i n a l H068 3>;>2K. / 5654=52=. ?@8<. D; 2 5 0 <;Q E v i n a l H0;>A 4/ 2A5E B8?>2 2>;>A D;. 2 5 0 28AB>5 ?8B0NI55 ;>G:> 4/ B5;0 A M:AB@. ?;0F5=BK BC10 1 5 0 <; $0@= - >4CA<5B8:0 ! D F a n t a s y (01J5;>A " 8=40;L, <54 8 ;>:>" D; 2 5 0 A<5B8:0) ( F I T O V A L H0B82 ?5@E>B8 D;. 1 0 0 @5A0=
%0A8:> , H A S I C O A?@59 8=B8 8 >A;5" D;. 1 2 5 <;9 H I R U D O A C T I V < E :@5B15;820NI89 BC10 6 0 :>=; H I R U D O A C T I V E :@5< 4/ ;8F0 8=B5=A82=K9 C2;06=ONI89 BC10 6 0 <;K H I R U D O A C T I V E :@5B C3@59 4/ ?@>1;568 A <0B8@CNI8< BC10 6 0 <;* H I R U D O A C T I V E :@5<- 10;L703 BC10 7 5 <;. H I R U D O A C T I V E :@5B @I8= BC10 6 0 <;5 H I R U D O A C T I V E :@568 2>:@C3 3;07 BC10 2 5 <;8 H I R U D O A C T I V E <0A:0 25==>9 :@0A>BK 4/ ;8F0 BC10 6 0 AL>=- B>=8: =>@9 8 :>68 " O i l P r o b l e m " D;. - 4>70B>@ 1 8 0 <;C H I R U D O D E R M ?5=OI89AO :@5< 4/ C70B>@ 1 8 0 =8: C2;06=ONI89 4/ ACE>9 8 =>@68 " E x t r a D r y " D;. - 4>70B>@ 1 8 0 =8: CA?>:0820NI89 >A2560NI89 " S e n s i t i v e " D;. - 4>70B>@ 1 8 0 <; Sagmel Inc. URGO LaboratoiresY I N D I V I T A :@5<?;5:A 4/ ;8F0 8 H58 A 0:B82=K< M=5@35B8G5A:8< 8 C2;06=ONI8< 5 0 <;
"@8B5=5@0 Q I N D I V I T A :@5<?;5:A 4/ ;8F0 8 H58 A @073;06820NI8< 8 45;8@CNI8< 5 0 <;H I N D I V I T A :@53> >;>65=8O 5 0 <;A I N D I V I T A ;LB5 2>AAB0=02;820NI0O 1 0 0 <;F I N D I V I T A ;LB5 A MDD5:B>< 0=B8AB@5AA0 1 0 0 <;T K E R A - N O V A 10;L70=48F8>=5@ 8=B5=A82=K9 C:@5?;ONI89 10=:0 4 5 0 @;>AA K E R A - N O V A 8=B5=A82=0O ?0AB0 >B ?5@E>B8 10=:0 2 0 0 ;>A> K E R A - N O V A :@5<- H0<?C=L 5654=52=K9 D;. 4 0 0 @;>AJ K E R A - N O V A B82 2K?045=8O 2>;>A 10=:0 4 5 0 ;>Ap K E R A - N O V A =48F8>=5@ " >AAB0=>2;5=85 70 3 <8=CBK" 10=:0 2 0 0 ;>A 68@=KE C :>@=59 8 ACE8E =0 :>=G8:0EU K E R A - N O V A =48F8>=5@ ?8B0B5;L=0O 10=:0 4 5 0 :@0H5==KE 8 ?>2@5645==KE 2>;>Aq K E R A - N O V A 25==K9 2>AAB0=>28B5;L AB@C:BC@K 2>;>A =5A<K205<K9 D;. - A?@59 2 7 5 :@0H5==KE 8 ?>2@5645==KE 2>;>A> K E R A - N O V A B5@- H0B82 2K?045=8O D;. 4 0 0 <;[ K E R A - N O V A H0AAB0=02;820NI89 ?8B0B5;L=K9 D;. 4 0 0 :@0H5==KE 8 ?>2@5645==KE 2>;>A` K E R A - N O V A H01J5AAB0=02;820NI89 D;. 4 0 0 ;>A 68@=KE C :>@=59 8 ACE8E =0 :>=G8:0E Berlin-Chemie AG/Menarini Group( L - "8@>:A8= 5 0 5@;8= %5<8 B01. 5 0 <:3 !5 0 :@8E8= Organon -@0B>@8O
Beiersdorf AG Eveline Orioni S A T I C O C r e a m y T o u c h B a m b o o & S a n d a l C o n d i t i o n e r :>=48F8>=5@ <O3:89 @0AB. c M:- <8 10<1C:0 8 A0=40;0 2 0 0 <; Saticot S A T I C O C r e a m y T o u c h B a m b o o S h a m p o o H0<?C=L < 10<1C:0 4/ C:@5?;5=8O 8 AB8AB0 2>;>A 2 0 0 =48F8>=5@ <O3:89 @0AB. c M:- < 65=LH5=O 8 2KH5=8O B>=CA0 2>;>A 2 0 0 <;s S A T I C O C r e a m y T o u c h G i n s e n g & H o n e y D e e p C h a r g e T r e a t m e n t ;>A <O3:0O @0AB. c M:- < 65=LH5=O 8 < 1 8 0 3z S A T I C O C r e a m y T o u c h G i n s e n g & H o n e y S h a m p o o H0<?C=L < 65=LH5=O 8 2KH5=8O B>=CA0 2>;>A 2 0 0 =48F8>=5@ <O3:89 @0AB. c M:- =A:8E @0AB5=89 2 0 0 <;t S A T I C O C r e a m y T o u c h J a p a n e s e F l o r a l D e e p C h a r g e T r e a t m e n t ;>A <O3:0O @0AB8B. A M:- =A:8E @0AB. 1 8 0 3m S A T I C O C r e a m y T o u c h J a p a n e s e F l o r a l S h a m p o o H0<?C=L 74>@>2;5=8O 2>;>A 2 0 0 <;o S A T I C O C r e a m y T o u c h S a n d a l S h a m p o o H0<?C=L <O3:89 @0AB. c M:AB- @3> 10;0=A0 2 0 0 =48F8>=5@- ?@>D. CE>4 4/ 8=B5=A82=>3> C2;06=5=8O A 42>9=K< 653> 1;5A:0 D;. 3 0 0 =48F8>=5@- ?@>D. CE>4 4/ ?@840=8O >1J59=K< 653> 1;5A:0 D;. 3 0 0 <;e S A T I C O p r e m i u m s t y l e :@5<- 3> C2;06=5=8O c 42>9=K< 653> 1;5A:0 2 5 0 3^ S A T I C O p r e m i u m s t y l e :@5<- :@0H5==KE 2>;>A c 42>9=K< 653> 1;5A:0 2 5 0 3] S A T I C O p r e m i u m s t y l e :@5<- 1J59=K< 653> 1;5A:0 2 5 0 3p S A T I C O p r e m i u m s t y l e H0D. CE>4 4/ 8=B5=A82=>3> C2;06=5=8O A 42>9=K< 653> 1;5A:0 D;. 3 0 0 <;% S I L C A F a m i l y ?0AB0 7C1=0O 1 0 0 <; BC10 Dental-Kosmetik GmbH6 S I L C A C i t r u s F r e s h + W h i t e n i n g ?0AB0 7C1=0O 1 0 0 <; BC100 S I L C A C o m p l e t e S e n s i t i v e ?0AB0 7C1=0O 1 0 0 <; BC10- S I L C A G o o d M o r n i n g ?0AB0 7C1=0O 1 0 0 <; ( BN18:) + S I L C A G o o d N i g h t ?0AB0 7C1=0O 1 0 0 <; ( BN18:) * S I L C A H e r b a l W h i t e ?0AB0 7C1=0O 1 0 0 <; BC10$ 8B0;L=KE 48015B>< B01. !3 0 8B0<8=K 4= 10;L70< 0@020520 D;. 1 0 0 = 10;L70< 0@020520 D;. 5 0 = M18 10;L70< 0@020520 D;. 3 0 =- ;N:A 10;L70< 0@020520 D;. 2 5 AB AC??. @5:B. !1 0 Medela AG KAB@C<35;L 35;L 2 , 5 % 3 0 3 BC10 LNB8- B01A !:8= !0= :0?A. !6 0 LNB8- B01A (0@< B01. !6 0 ( ) Bubchen4 N1E5= " 84A" :@5A<5B. 45BA:89 10=:0 7 5 <; 0;8=00 N1E5= " 84A" ;>G:> 4;O B5;0 1@8:>A D;. 2 0 0 <;G N1E5= 10;L7068 " 0;5=4C;0" BC10 4 0 G. ACE>9 8 @074@06. :>68' N1E5= 35;L 4;O :C?0=8O <;045=F52 4 0 0 <;@ N1E5= :@5< 4/ ;8F0 " 0;5=4C;0" 10=:0 7 5 9 8 GC2AB2. :>684 N1E5= :@5< 4/ ;8F0 8 B5;0 " 56=K9" C2;06=ONI89 2 0 0 <; N1E5= :@5< 4/ <;045=F52 1 5 0 <;, N1E5= :@5A<5B8G5A:89 10=:0 7 5 <;& N1E5= :@5< 70I8B=K9 1 0 0 <; A?5F80;L=K92 N1E5= :@53>45 BC10 7 5 A" N1E5= :@53>45 BC10 7 5 AL>= 4;O :C?0=8O 2 - D07=K9 4 0 0 AL>= CE06820NI89 2 0 0 <; " 5@5ABL 8 3@C4=>5 2A:0@<;820=85" N1E5= 4/ <;045=F52 2 0 0 <;6 N1E5= 4/ CE>40 70 :>659 45B59 A :0;5=4C;>9 2 0 0 <;C N1E5= 5 2 0 0 <; " 5@5ABL 8 3@C4=>5 2A:0@<;820=85" N1E5= ;>G:> 2 0 0 <; N1E5= 45BA:>5 1 2 5 3 N1E5= ?@8AK?:0 45BA:0O 1 2 5 3 N1E5= A0;D5B:8 2;06=K5 !1 5 0 * N1E5= A0;D5B:8 2;06=K5 !1 5 0 70?0A=>9 1;>:# N1E5= A0;D5B:8 2;06=K5 !7 2 >@B2 N1E5= H0;>A 8 B5;0 2 5 0 A N1E5= H0<?C=L 45BA:89 2 0 0 <;3 N1E5= H0;>A 8 B5;0 2 5 0 @<OI8E 45;L 0 0 1 0 ) B NAB30;B5@ " ;5=0" 4/ :>@<OI8E 45;L 0 0 1 0 ) B NAB30;B5@ " ;5=0" 4/ :>@<OI8E 45;L 0 0 1 0 ) B NAB30;B5@ " ;5=0" 4/ :>@<OI8E 45;L 0 0 1 0 ) B NAB30;B5@ " ;5=0" 4/ :>@<OI8E 45;L 0 0 1 0 ) B NAB30;B5@ " ;5=0" 4/ :>@<OI8E 45;L 0 0 1 0 ) P NAB30;LB5@ ?>A;5@>4>2>9 E/ 1 B@8:>B06=K9 - " $-!"- 1 " @. 8 0 D ( 15;K9) ( 45;L 1 8 3 1 ) P NAB30;LB5@ ?>A;5@>4>2>9 E/ 1 B@8:>B06=K9 - " $-!"- 1 " @. 8 0 ! ( 15;K9) ( 45;L 1 8 3 1 ) P NAB30;LB5@ ?>A;5@>4>2>9 E/ 1 B@8:>B06=K9 - " $-!"- 1 " @. 8 5 D ( 15;K9) ( 45;L 1 8 3 1 ) P NAB30;LB5@ ?>A;5@>4>2>9 E/ 1 B@8:>B06=K9 - " $-!"- 1 " @. 8 5 ! ( 15;K9) ( 45;L 1 8 3 1 ) - 8= & 03>B8; @- @ 4/ =0@C6. ?@8AB0= ;8>D. 4/ ?@83. @- @0 4/ 8=D. 2 0 <:3 02>5 2 5 <;" 070=A:0O D0@<0F52B8G5A:0O D01@8:0 078;8? B01. 4 0 1 0 1 0 2 0 2 0 4 0 4 0 1@0; >@0;. @- @ 5 0 1@0; B01. !3 0 07>:0@48= B01. 1 0 0 :0@48= B01. 5 0 <3 !5 0 Lannacher HeilmittelB 0:A83@8? H?@8F 0 , 5 70 ( 4/ 27@>A;KE 8 45B59 >B 3 ;5B 8 AB0@H5) Merck Sharp & Dohme !"- 548D0@@=528I0 A :>@=O@=528I0 A :>@=O 0 , 2 0 5 3 !1 0 0 ( ) 0;5@80=0E5;L :0?;8 D;. 3 0 0 , 0 2 3 !1 0 8 0;5@80=K M:- B B01. ?/ > 0 , 0 2 3 !5 0 ( 10=:8 B53> AB5:;0) , 0;5@80=K M:AB@0:B B01. ?/ > 2 0 ; :0?A. 0 , 0 5 3 !2 0 $0@; A 3;N:>7>9 B01. !1 0 0;84>; B01. 0 , 0 6 3 !1 0 0;84>; B01. ?>4JO7. 0 , 0 6 3 !1 0 0;>:>@48= :0?;8 D;. 2 0 :>@48= :0?;8 D;. 5 0 A5@48= 1 5 A5@48= 2 5 <; 0;B@5:A B01. 5 0 0 D. 4/ ?@83. @- @0 4/ 8=D. 1 0 0 0 G:0 " 0A:>2K5 @C:8" 4/ A68 @C: 8 C:@5?;5=8O =>3B59 D;. 3 0 0 31 0==>G:0 4/ =>3 25G5@=OO " '09=>5 45@52>" D;. 4 4 0 <54 B01. 2 , 5 @>4A:89 7- 4# 0B0 38385=8G5A:0O 2 5 3 =5AB5@8;L=0O# 0B0 38385=8G5A:0O 5 0 3 =5AB5@8;L=0OA 0B0 A0=8B0@=>- 38385=8G5A:0O 1 0 0 3 =5AB5@8;L=0O E;>?:>20O " <5;8O" , 0B0 E8@C@38G5A:0O 2 ?/ M ?0:5B5 5 0 3 " ?:>20O " <5;8O" # 0B0 E8@C@38G5A:0O =5AB5@8;L=0O 2 5 37 0B0 E8@C@38G5A:0O AB5@8;L=0O 1 0 0 3 <548F8=A:0O " <5;8O" 0B=K5 48A:8 " / A0<0O" !1 2 0
Group Lemoine 0B=K5 48A:8 O L A ! !8 0
CELLTEX S.R.O% 0B=K5 48A:8 :@C3;K5 !8 0 H e l e n H a r p e r Ontex! 0B=K5 H0@8:8 " <5;8O" !1 0 0 ( 7 0 3) 0B=K5 H0@8:8 " << 5;8O" !5 0 ( 3 5 3) 0B=K5 H0@8:8 !8 0 H e l e n H a r p e r # 0B=K5 H0@8:8 F25B=K5 " 5 5 <3 !3 0 5;0:A8= B01. 3 7 , 5 <3 !2 8 5;102:0 4/ 20== D;. 2 0 0 102:0 4/ 20== D;. 2 0 0 102:0 4/ 20== D;. 2 0 0 102:0 4/ 20== D;. 3 0 102:0 4/ 20== D;. 2 0 0 102:0 4/ 20== D;. 2 0 0 102:0 4/ 20== D;. 2 0 0 102:0 4/ 20== D;. 2 0 0 <; 5=5= 35;L 4- @0 "09AA0 1 0 0 3# 5=70 :0?;8 4/ 2=CB@. ?@8<. D;. 2 0 <; 5=8B0= 35;L 1 % 5 0 3 5=8B0= :@57>; 35;L BC10 5 0 7>; :@5< BC10 5 0 7>; B01. !3 6 5=>7>; B01. !6 0 5=>:>@A5B :0?A. !1 5 5=>?8;A :0?A. 2 7 0 = Willmar Schwabe 5=>@CB>= 35;L 2 % 4 0 3 Novartis Consumer Health 5=>@CB>= :0?A. 3 0 0 @@0AB2. :0?A. !3 0 ; 8D8D>@2>- 2K9 2:CA) 9 8D8D>@@. A0H5 !2 1 ( 0?5;LA8=>2>- 2K9 2:CA) 8F8;;8= 3 6 0 0 BKA. 54. D;. 8H>D8B 35;L " 8H>;8=" 1 3 0 3 ?;NA ;5<0@5= 3@0=C;OB 2 0 0 33 ;5=0D. ?>@. 4/ ?@83. @- @0 4/ 8=. D;. 1 5 !1 Nippon Kayaku Co Ltd( ;5>F8= ;8>D. 4/ ?@83. @- @0 4/ 8=. 1 5 <3 !1 = ;5A: 4/ 3C1 45BA:89 " @8=F5AA0" 5 - @>7>2K9 A> A?>=65;>@ 5:>@/ ! - 8H5;L Dr. Schmidgall >48 AB8;L ?8;N;8 !1 0 0 >48=5D>A :0?A. 4 0 0 =5D>A B01. ?/ > 8 0 0 =8A0= :0?A. 5 8 9 @0>@0 :0?A. 3 5 0 @=>9 :- BK A?8@B. @- @ 3 % D;. 2 5 @> 59@ :@5@> 59@ :@5@> 59@ :@57>2K9 >@> ;NA :@5@> ;NA :@57>2K9% >@>20O A25;;8O :@5< BC10 5 0 <; 8B8CA @02538; 0<?. 1 <3/ <; 2 = @- @ 4/ 8=D. 0 , 5 % 0<?. 2 <; !1 0 @0; 0<?. 5 <; !5 Micro Lab. Ltd. @0; B01. 5 0 0 EC45=8O @. L K.W.Innovations" @8468 " A r t e m i s " 4/ ?>EC45=8O @. X L B @8468 F a r m a C e l l A :0?AC;0 !2 0 @>700@ B01. ?/ > 0 , 0 5 3 !1 4 = @><35:A8= 4 5@;8=- %5<8 @- @ 4/ ?@85<0 2=CB@L 4 <3/ 5 <; D;. 6 0 <35:A8= 8 5@;8=- %5<8 4@. 8 <35:A8= 8 :0?;8 2 0 <35:A8= <8:ABC@0 0 , 8 <3/ <; 1 5 0 <35:A8= B01. 8 <35:A8= B01. 8 <35:A8= B01. 4/ 45B59 4 :@8?B8=- 8EB5@ B01. 2 , 5 =E0;8A- E5;L B01. !5 0 Rhone-Poulenc Rorer/Boots% @>=E8:C? >B :0H;O 1 3 0 3 ( 1 0 0 =E8?@5B :0?;8 4/ ?@85<0 2=CB@L D;. 5 0 =E>- <C=0; :0?A. 7 =E>- <C=0; :0?A. 3 , 5 =E>1>A A8@>? 1 2 5 <3/ 5 <; D;. 2 0 0 =E>1>A A8@>? 2 5 0 <3/ 5 <; D;. 2 0 0 =E>;8B8= D;. 1 2 5 3 @>=E>A0= :0?;8 2 5 7 2 5 <3 !1 0 RanbaxyA @N:8 F a r m a C e l l A :0?AC;0<8 F u s e a u x C l a s s i c @. L / X L ( G5@=K9) @ @N:8 F a r m a C e l l A :0?AC;0- ?@>4C:B Kimberly Clark $0@ CA5@5;8=0 0F5B0B0 @- @ 0 . 2 % A?@59 =07. D;. 1 7 , 5 78@>20==K9 CA:>?0= B01. ?/ > 1 0 = @D0=>;0 B0@B@0B @- @ 0 , 2 % 1 @D0=>;0 B0@B@0B @- @ 0 , 2 % 1 G:0 4/ :>@<;5=8O A V E N T 1 2 5 G:0 4/ :>@<;5=8O A V E N T 1 2 5 G:0 4/ :>@<;5=8O A V E N T 2 6 0 G:0 4/ :>@<;5=8O A V E N T 3 3 0 G:0 4/ :>@B82>:>;8:>20O 2 3 7 :8@;>G:0 4/ :>@B82>:>;8:>20O 2 3 7 AB0=4. 3>@;>G:0 ?;0AB8:>20O 0=B8:>;8:>20O A A8;8:>=>2>9 A>A:>9 2 2 5 G:0 ?;0AB8:>20O A A8;8:>=>2>9 A>A:>9 2 5 0 G:0 ?;0AB8:>20O A B0;859 A A8;8:>=>2>9 A>A:>9 3 0 0 G:0 A ;0B5:A=>9 A>A:>9 1 4 0 A8:8" ( 1 1 0 0 2 ) 6 CBK;>G:0 A ;0B5:A=>9 A>A:>9 2 6 0 A8:8" ( 1 1 0 0 6 ) B CBK;>G:0 A @CG:0=>2>9 A>A:>9 1 4 0 A8:8" ( 1 1 0 0 0 ) 6 CBK;>G:0 A @CG:0=>2>9 A>A:>9 2 5 0 G:0 A @CG:0=>2>9 A>A:>9 3 0 0 G:0 A A8;8:>=>2>9 A>A:>9 1 4 0 A8:8" ( 1 1 0 0 1 ) 8 CBK;>G:0 A A8;8:>=>2>9 A>A:>9 2 6 0 <; " CA8:8" ( 1 1 0 0 4 ) 7 CBK;>G:0 AB5:;O==0O A A8;8:>=>2>9 A>A:>9 1 2 5 <; ( 1 1 0 1 8 ) 5B0A5@: B01. 8 = ;8>D. 4/ ?@83. @- @0 4/ 8=. 9 , 6 <?;. A @- ;5; A25G8 !1 0 !B@5;5F D8@- :@53 BC10 7 5 <; 5DC=38= D;. 1 0 0 <; =40AB@8 60@>1C4C@ ". 87>= ?>@. 3 3 !1 0@0D0@B@8< B01. 4 8 0 18; :0?A. 4 0 18; :0?A. 4 0 18; D>@B5 :0?A. 8 0 6 0 0 @ & Tosama
0;L=8F05<K9 ( 8=B ;8?:89 8=B;8) 1 0 A< E2 0 0 A=8F05<K9 1 0 A< E2 5 A<4 8=B <548F8=A:89 M;0AB8G=K9 A0:;5NI89AO 4 , 5 < E7 5 << Tonus Elast 8=B =5AB5@8;L=K9 5 < E1 0 A2 '
83@>20B0 8=B @578=>2K9 0@B5=A0 3 , 5 < 8523C2K9 0@B5=A0 5 ;5=>AB>?=K9 @07;5=>AB>?=K9 @07==K9 " =B5:A" 2KA>:>9 @0ABO68AB8 1 < E8 A==K9 " =B5:A" 2KA>:>9 @0ABO68AB8 2 < E1 0 A==K9 " =B5:A" 2KA>:>9 @0ABO68AB8 5 < E1 0 A==K9 " =B5:A" 9 @0ABO68AB8 1 , 5 < E8 A==K9 " =B5:A" 9 @0ABO68AB8 2 , 5 < E1 0 A==K9 " =B5:A" 9 @0ABO68AB8 3 < E1 0 A==K9 " =B5:A" 9 @0ABO68AB8 5 < E8 A 8=B M;0AB8G=K9 <548F8=. 5 < E8 A< ( 9 5 1 2 ) A <5B0;. 70AB56:0<8# 8=B M;0AB8G=K9 <548F8=. 3 < E8 A<- 8=B M;0AB8G=K9 <548F8=. ! 0 , 6 < E8 A@<0" + 8=B M;0AB8G=K9 <548F8=. ! 2 < E8 A@<0" - 8=B M;0AB8G=K9 <548F8=. ! 3 , 5 < E8 A@<0" 6 8=B M;0AB8G=K9 <548F8=. # - 3 < E1 0 A< A 70AB56:0<8( 8=B M;0AB8G=K9 <548F8=. # - 3 < E8 A<5 8=B M;0AB8G=K9 <548F8=. # - 5 < E8 A< A 70AB56:0<8* 8=B M;0AB8G=K9 <548F8=. # - ! 1 , 5 < E8 A<) 8=B M;0AB8G=K9 <548F8=. # - ! 3 < E1 0 A<( 8=B M;0AB8G=K9 <548F8=. # - ! 3 < E8 A<( 8=B M;0AB8G=K9 <548F8=. # - ! 5 < E8 A<0 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 1 , 0 < E1 0 A</ 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 1 , 0 < E8 A<0 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 1 , 5 < E1 0 A</ 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 1 , 5 < E8 A<0 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 2 , 0 < E1 0 A</ 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 2 , 0 < E8 A<0 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 2 , 5 < E1 0 A<0 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 3 , 0 < E1 0 A</ 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 3 , 0 < E8 A</ 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 3 , 5 < E8 A</ 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 4 , 0 < E8 A</ 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 4 , 5 < E8 A</ 8=B M;0AB8G=K9 A 70AB56:0<8 " =B5:A" 5 , 0 < E8 A<' 8=B M;0AB8G=K9 A5BG0BK9 @07<. 1 ( 9 7 0 1 ) ' 8=B M;0AB8G=K9 A5BG0BK9 @07@B82=K9 # - #! 1 , 5 < E8 A9 ;8?CG:>9B 8=B M;0AB8G=K9 A?>@B82=K9 # - #! 2 , 0 < E8 A9 ;8?CG:>9B 8=B M;0AB8G=K9 A?>@B82=K9 # - #! 3 , 0 < E8 A9 ;8?CG:>9% 8=B M;0AB8G=K9 B@C1G0BK9 2 5 < @07- ?>;8MD8@=K9 " =B5:A" @07<. 1 . 8=B M;0AB8G=K9 B@C1G0BK9 @07<. 2 =5AB5@8;L=K9. 8=B M;0AB8G=K9 B@C1G0BK9 @07<. 3 =5AB5@8;L=K9. 8=B M;0AB8G=K9 B@C1G0BK9 @07<. 4 =5AB5@8;L=K9. 8=B M;0AB8G=K9 B@C1G0BK9 @07- 0:A B01. ?/ > !3 0 8>- 0:A B01. ?/ > !6 0 8>:B82 >;>:=> 8 0 B01. !6 0 Pharma Nord 8>:B82 !5;5=+ &8=: B01. !3 0 8>:B82 %@>AB8= :0?A. 0 , 5 3 !3 0 8>28B0;L 35;L 1 7 5 3 4/ 45B59 20=- 40- 0@LO 2@>?0- 8>D0@:A B01. 3>?0B. ?>4JO7. !4 5 ?0@>:A 8=3. 4 0 0 4>7 2 0 <; Frenchi Products, Inc.3 M a r v e l L i f e S c i e n c e s / #D028B0 #D8<A:89 28B0AC;8= ACA?. 4/ 8=. 1 0 0 / <; 3 AC;8= @- @ 4/ 8=. 1 0 0 / <; :0@B@8468 3 B8:8 8>B@548= B01. !3 0 8A0:>48; A25G8 1 0 48; AC??. 1 0 48; B01. ?/ > 5 48;- 86D0@< A25G8 1 0 ; 4 8 0 0<?. 5 ; ACA?. D;. 8 0 ; B01. 1 2 0 ; B01. 4 8 0 30< 5 <3 !3 0 8D0A0< :@5< 1 % BC10 3 0 3 !0<0@0< ; 8D84C<10:B5@8= ( 1 0 0 10:B5@89/ B01. ) B01. D;. !3 0 # 8D84C:04 8D84C@. 5 4>7 !1 0 0@B=5@ 8D84C@. 5 4>7 !3 < 0$ 8D84C@. 5 0 0 <;=. !1 0 8D84C9 A25G8 !1 0 $ 8D84C@B5 ?>@. 5 4>7 !3 0 8D8:>; D;. 5 4>7 !1 0 Ferrosan? 0=406 ?@8 >?CI5=88 2=CB@5==8E >@30=>2 - " "@825A" ( "- 6 1 ) @. X L ; 0=406 ?@>B82>@048:C;8B=K9 -- " "@825A" ( "- 5 2 ) @. X L 65AB:895 0=406 B@8:>B06=>- M;0AB8G=K9 - #=30 " !C?5@" @07=CA 5 0=406 B@8:>B06=>- M;0AB8G=K9 - #=30 " !C?5@" @07B06=>- M;0AB8G=K9 - #=30 " !C?5@" @07B06=>- M;0AB8G=K9 - #=30 " !C?5@" @07B06=>- M;0AB8G=K9 - #=30 " !C?5@" @07B06=>- M;0AB8G=K9 - #=30 " !C?5@" @07B06=>- M;0AB8G=K9 - #=30 " !C?5@" @07B06=>- M;0AB8G=K9 - #=30 " !C?5@" @07B06=>- M;0AB8G=K9 - #=30 " #=825@A0;" @07B06=>- M;0AB8G=K9 - #=30 " #=825@A0;" @07B06=>- M;0AB8G=K9 - #=30 " #=825@A0;" @07B06=>- M;0AB8G=K9 - #=30 " #=825@A0;" @07B06=>- M;0AB8G=K9 - #=30 " #=825@A0;" @07B06=>- M;0AB8G=K9 - #=30 " #=825@A0;" @07F8= <07L 2 0 3 Biochemie8 0=:8 ACE85 20:CC;8- AB5:;O==K5 - 0 1 - " " !2 ;L?8=0 ;0AB 8 0=:8 ACE85 20:CC;8- AB5:;O==K5 - 0 1 - " " !8 8?A- 54 Hoechst/India/Ltd) 0@0;38= @- @ 4/ 8=. 5 0 0 <3/ <; 0<?. 5 20; :0?;8 D;. 2 5 A8;0 $0:5;- 48709= 0B@0D5= :@53B59 8 % 3 3 ( D;. A :@KH:>9- :8AB>G:>9) Apexmed International B.V. AVL 0N- 109 D;. 2 5 <; Dentinox1 5918 0;? 4/ <;045=F52 D;. 1 5 70B>@>= B01. !6 $ 5:;07>= - 0M@. 1 0 0 70 2 0 0 4>72 5:;07>= - 0M@. 4/ 8=3. 4>7
raymond weil
hp
5004.14 ()
5004.14 ()
5004.14 ()
5004.14 ()
5004.14 ()
5004.14 ()
5004.14 ()
5004.14 ()
5004.14 ()
5004.14 ()
5004.14 ()
5004.14 ()
.